Board of Directors
Sean P. Nolan
Sean P. Nolan is the chairman of the board of directors at Encoded Therapeutics.
Until its acquisition in 2018 by Novartis, he served as chief executive officer and member of the board of directors of AveXis, Inc., a gene therapy company dedicated to development of novel treatments for patients suffering from rare and life-threatening neurological diseases. While at AveXis, Sean took the company through an IPO and built it into a fully integrated global organization with research, clinical, regulatory, manufacturing and commercial capabilities.
Prior to joining AveXis, Sean was the chief business officer of InterMune, Inc., a company focused on development of therapies for fibrotic disease. He led the successful scale up, commercialization of the first drug for Idiopathic Pulmonary Fibrosis and successful acquisition by Roche, Inc. Sean’s previous experiences include chief commercial officer of Reata and Ovation Pharmaceuticals, Inc. as well as president of Lundbeck, Inc.’s U.S. affiliate after acquiring Ovation in 2009.
Sean holds a B.A. in Biology from John Carroll University and serves on the board of Aquinox Pharmaceuticals, Inc.